NGM Biopharmaceuticals, Inc.

26 articles with NGM Biopharmaceuticals, Inc.

• NGM Bio Announces Preliminary Results from Phase 1b Study of NGM313 in Obese, Insulin Resistant Subjects with Nonalcoholic Fatty Liver Disease (NAFLD)

  11/12/2018

  Single dose of NGM313 resulted in statistically significant reductions in liver fat content and multiple metabolic parameters of NASH and Type 2 diabetes

• NGM Bio Announces New Histology Data from Phase 2 Trial of NGM282 in Patients with NASH

  11/9/2018

  NGM Biopharmaceuticals, Inc., a clinical stage biotechnology company focused on harnessing powerful biology to develop transformative therapeutics for patients, today announced preliminary histology data from open-label, single-blind, dose-finding expansion cohorts of its Phase 2 study evaluating its lead product candidate, NGM282, in patients with nonalcoholic steatohepatitis (NASH).

• NGM Bio Announces Multiple Presentations at AASLD's The Liver Meeting®, Including New NASH Histology Data from the Phase 2 Trial of NGM282 and Topline Phase 1b Data for NGM313

  11/6/2018

  NGM Biopharmaceuticals, Inc. today announced multiple presentations at AASLD's The Liver Meeting® 2018, which will take place in San Francisco from November 9-13, 2018.

• NGM Bio Appoints David J. Woodhouse, Ph.D. as Chief Executive Officer and Aetna Wun Trombley, Ph.D. as President and Chief Operating Officer

  10/1/2018

  Suzanne Sawochka Hooper Joins NGM's Board of Directors

• NGM Bio Announces Publication In The Lancet Of Phase 2 Study Of NGM282 In NASH Patients And Upcoming Presentations Of NGM282 NASH Histology Data And NGM282 PSC Data At The International Liver Congress 2018

  3/12/2018

  Statistically significant and clinically meaningful improvements observed in MRI measures of liver fat and serum biomarkers of liver function, lipid metabolism and fibrosis

• Ablexis Announces Licensing of the AlivaMab Mouse to NGM Biopharmaceuticals

  1/5/2018

  The non-exclusive license grants NGM rights to use the AlivaMab Mouse for antibody drug discovery and development.

• NGM Bio Provides Update on NGM282 in NASH

  10/19/2017

  NGM Bio today provided an update on the development of NGM282, a compound in Phase 2 clinical testing for the treatment of NASH.

• NGM Release: Study Published In Nature Reveals Molecular Pathway Of Weight-Controlling Hormone, Enabling The Discovery Of Multiple Drug Candidates For Obesity And Cachexia

  10/3/2017

• NGM Announces NGM282 Dramatically Reduced Liver Fat And Other Biomarkers Associated With Nonalcoholic Steatohepatitis (NASH) In Phase II Trial

  4/24/2017

• NGM Initiates Phase 1 Clinical Trial Of NGM313, A Proprietary Antibody With The Potential To Treat Type 2 Diabetes, Obesity And NASH

  6/8/2016

• Nine Bay Area Biotechs Vie to be the “Next Genentech”

  5/26/2016

• Booming Bay Area Biotech NGM Plans Move to Vacant Site Once Meant for Amgen

  5/5/2016

• NGM To Present New Data On NGM282 At The European Association For The Study Of The Liver International Liver Congress 2015

  4/20/2015

• NGM Announces Positive Phase II Clinical Data In Primary Biliary Cirrhosis Patients For NGM282, A First-In-Class Investigational Medicine

  3/24/2015

• Backed By a Genentech Alum, NGM Looks Like it Could be the Next Biotech IPO

  3/5/2015

• NGM Announces Expansion Of Management Team

  3/2/2015

• How Merck & Co.'s R&D Chief Saved NGM Deal With a Juicy Pitch

  2/27/2015

• Merck & Co. Bets $450 Million on Bay Area's NGM

  2/24/2015

• NGM Biopharmaceuticals, Inc. Locks Down $50 Million Series C

  7/18/2013

• AstraZeneca PLC and NGM Biopharmaceuticals, Inc. Form Diabetes/Obesity Partnership

  6/17/2013